AGM 130

Drug Profile

AGM 130

Alternative Names: AGM 130

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnyGen
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 11 Mar 2017 AnyGen has patents pending for AGM 130 in USA, Japan, Korea and Europe
  • 10 Mar 2017 Phase-I clinical trials in Breast cancer in South Korea (IV) before March 2017 (AnyGen pipeline, March 2017)
  • 30 Oct 2014 Pharmacodynamics data from a preclinical study in Breast cancer released by AnyGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top